Zurcher Kantonalbank Zurich Cantonalbank Acquires 4,256 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 67.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,588 shares of the medical research company's stock after acquiring an additional 4,256 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Bio-Rad Laboratories were worth $3,478,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Venturi Wealth Management LLC lifted its position in shares of Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after purchasing an additional 87 shares during the period. Gladius Capital Management LP acquired a new stake in Bio-Rad Laboratories during the 3rd quarter worth about $32,000. Asset Planning Inc bought a new position in shares of Bio-Rad Laboratories in the 4th quarter worth about $33,000. UMB Bank n.a. lifted its stake in shares of Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after purchasing an additional 32 shares during the period. Finally, Cape Investment Advisory Inc. bought a new stake in shares of Bio-Rad Laboratories during the 4th quarter valued at about $38,000. 65.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Wells Fargo & Company lowered their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. StockNews.com cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Bio-Rad Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $395.20.

Remove Ads

Bio-Rad Laboratories Stock Performance

Shares of NYSE BIO traded down $6.54 during mid-day trading on Wednesday, reaching $253.49. 282,789 shares of the company's stock were exchanged, compared to its average volume of 264,458. The firm has a 50-day moving average price of $308.56 and a two-hundred day moving average price of $326.91. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. Bio-Rad Laboratories, Inc. has a 52 week low of $244.00 and a 52 week high of $387.99. The firm has a market capitalization of $7.10 billion, a price-to-earnings ratio of -3.90 and a beta of 0.98.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.